DE69434328D1 - TAT transdominante Variante aus Human Immunodeficiency Virus - Google Patents

TAT transdominante Variante aus Human Immunodeficiency Virus

Info

Publication number
DE69434328D1
DE69434328D1 DE69434328T DE69434328T DE69434328D1 DE 69434328 D1 DE69434328 D1 DE 69434328D1 DE 69434328 T DE69434328 T DE 69434328T DE 69434328 T DE69434328 T DE 69434328T DE 69434328 D1 DE69434328 D1 DE 69434328D1
Authority
DE
Germany
Prior art keywords
immunodeficiency virus
human immunodeficiency
tat
variant
contg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69434328T
Other languages
English (en)
Other versions
DE69434328T2 (de
Inventor
Majid Mehtali
Tania Sorg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transgene SA
Original Assignee
Transgene SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene SA filed Critical Transgene SA
Publication of DE69434328D1 publication Critical patent/DE69434328D1/de
Application granted granted Critical
Publication of DE69434328T2 publication Critical patent/DE69434328T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE69434328T 1993-01-04 1994-01-03 TAT transdominante Variante aus Human Immunodeficiency Virus Expired - Fee Related DE69434328T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9300004A FR2700169B1 (fr) 1993-01-04 1993-01-04 Nouveaux variants trans-dominants TAT du virus de l'immunodéficience humaine.
FR9300004 1993-01-04

Publications (2)

Publication Number Publication Date
DE69434328D1 true DE69434328D1 (de) 2005-05-19
DE69434328T2 DE69434328T2 (de) 2006-03-09

Family

ID=9442808

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69434328T Expired - Fee Related DE69434328T2 (de) 1993-01-04 1994-01-03 TAT transdominante Variante aus Human Immunodeficiency Virus

Country Status (10)

Country Link
US (2) US5889175A (de)
EP (3) EP1580272A3 (de)
JP (2) JP3613734B2 (de)
AT (1) ATE292981T1 (de)
AU (1) AU668441B2 (de)
CA (1) CA2112652A1 (de)
DE (1) DE69434328T2 (de)
DK (1) DK0614980T3 (de)
ES (1) ES2236688T3 (de)
FR (1) FR2700169B1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2731355B1 (fr) * 1995-03-08 1997-05-30 Neovacs Nouveaux immunogenes, nouveaux anticorps, procede de preparation et compositions pharmaceutiques les renfermant
PL322143A1 (en) * 1995-03-08 1998-01-05 Neovacs Non-topxic immunogenes originating frommretroviral regulator protein, antibodies as such, method of preparing them and pharmaceutic compositions containing them
US5885806A (en) * 1995-11-28 1999-03-23 The Johns Hopkins University School Of Medicine Methods to prepare conditionally replicating viral vectors
US5888767A (en) 1996-11-27 1999-03-30 The Johns Hopkins University School Of Medicine Method of using a conditionally replicating viral vector to express a gene
ES2175355T3 (es) * 1996-01-29 2002-11-16 Virologic Inc Composiciones y metodos para determinar la susceptibilidad y la resistencia a farmacos antivirales y rastreo de farmacos antivirales.
US6686333B1 (en) * 1996-10-04 2004-02-03 The United States Of America As Represented By The Department Of Health And Human Resources Inhibition of HIV replication using soluble Tat peptide analogs
AU4663297A (en) * 1996-10-04 1998-04-24 Government Of The United States Of America, The Inhibition of hiv replication using soluble tat peptide analogs
US5891994A (en) * 1997-07-11 1999-04-06 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
FR2792204B1 (fr) * 1999-04-13 2001-07-13 Centre Nat Rech Scient Vaccin anti-vih-1 comprenant tout en partie de la proteine tat de vih-1
FR2792206B1 (fr) * 1999-04-13 2006-08-04 Centre Nat Rech Scient Vaccin anti-vih-1 comprenant tout ou partie de la proteine tat de vih-1
US20050226890A1 (en) * 1999-08-12 2005-10-13 Cohen David I Tat-based vaccine compositions and methods of making and using same
CA2398269C (en) * 1999-08-12 2013-04-09 David I. Cohen Non-immunosuppressant hiv tat
US8323928B2 (en) 1999-08-12 2012-12-04 Pin Pharma, Inc. Vaccines and immunotherapeutics derived from the human immunodeficiency virus (HIV) transactivator of transcription protein for the treatment and prevention of HIV disease
US6399067B1 (en) * 2000-04-28 2002-06-04 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
WO2005090392A1 (en) * 2004-03-16 2005-09-29 Inist Inc. Tat-based tolerogen compositions and methods of making and using same
US6946267B2 (en) * 2002-03-13 2005-09-20 Dr. Chip Biotechnology Inc. Method for detecting Staphylococcus aureus
US20050208482A1 (en) * 2004-03-16 2005-09-22 Cohen David I Tat-based immunomodulatory compositions and methods for their discovery and use
EP1851247A2 (de) 2005-02-15 2007-11-07 Thymon L.L.C. Verfahren und zusammensetzungen zur behinderung der vervielfältigung von hiv-1
CA2755897C (en) 2009-03-23 2020-01-28 Nanirx, Inc. Treatment of cancers with immunostimulatory hiv tat derivative polypeptides
IT1397569B1 (it) 2009-12-10 2013-01-16 Icgeb Peptidi e loro derivati che inibiscono il rilascio extracellulare della proteina tat di hiv-1 e la replicazione di hiv-1.
FR2982277B1 (fr) 2011-11-08 2015-08-21 Agronomique Inst Nat Rech Cassette d'expression inductible et ses utilisations
WO2015051245A1 (en) 2013-10-04 2015-04-09 Pin Pharma, Inc. Immunostimulatory hiv tat derivative polypeptides for use in cancer treatment

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989012461A1 (en) * 1988-06-16 1989-12-28 St. Louis University Antagonists of viral transactivating proteins

Also Published As

Publication number Publication date
ATE292981T1 (de) 2005-04-15
JPH06234791A (ja) 1994-08-23
EP1580272A2 (de) 2005-09-28
EP1580272A3 (de) 2005-10-05
EP1424394A2 (de) 2004-06-02
EP0614980A1 (de) 1994-09-14
EP0614980B1 (de) 2005-04-13
DK0614980T3 (da) 2005-08-08
AU668441B2 (en) 1996-05-02
JP2004065256A (ja) 2004-03-04
FR2700169A1 (fr) 1994-07-08
FR2700169B1 (fr) 1995-03-24
AU5280393A (en) 1994-07-14
EP1424394A3 (de) 2005-10-05
US6284252B1 (en) 2001-09-04
ES2236688T3 (es) 2005-07-16
DE69434328T2 (de) 2006-03-09
US5889175A (en) 1999-03-30
JP3613734B2 (ja) 2005-01-26
CA2112652A1 (fr) 1994-07-05

Similar Documents

Publication Publication Date Title
DE69434328D1 (de) TAT transdominante Variante aus Human Immunodeficiency Virus
ATE173478T1 (de) Varianten des pankreatischen rinder- trypsininhibitors, deren herstellung und verwendung
EP0728764A4 (de) Peptide das eine immunantwort gegen hiv unduziert und arzneimittel die esenthaelt zur vorbeugung oder behandlung von aids
WO1989009787A3 (en) Osteogenic devices
TR199501134A2 (tr) Memeli ve viral proteinleri asiri ifade edilmesi.
NO20100324L (no) Fremgangsmate for trinnvis festing av polyetylenglykol (PEG) andeler i serie til et polypeptid
AR009436A1 (es) UNA PROTEíNA DE FUSIoN FC-OB, UNA SECUENCIA DE ÁCIDO NUCLEICO QUE LA CODIFICA, UN VECTOR, PROCEDIMIENTO DE PREPARACIoN, COMPOSICIONES FARMACÉUTICAS Y USOS.
AU4978496A (en) Encapsidated recombinant poliovirus nucleic acid
ATE64619T1 (de) Menschliches apolipoprotein a1 sowie dessen variante, exprimiert in escherichia coli.
GR852940B (de)
NO910982D0 (no) Uratoksydase-aktivt protein, rekombinant gen som koder for det, ekspresjonsvektor, mikroorganismer og transformerteceller.
DE3881023D1 (de) Proteine, expressionsvektoren, die fuer solche proteine kodierende dna enthalten und zellen, die solche expressionsvektoren enthalten.
DK0728208T3 (da) Tomat-xyloglucan-endo-transglycosylase
FR2732346B1 (fr) Proteines mutees, codees par un gene env mute de lentivirus, fragments peptidiques inclus dans lesdites proteines, vecteurs d'expression exprimant lesdites proteines mutees et leurs applications
EP1251176A3 (de) Expressionssysteme, die selbstspaltende Fusionsproteine verwenden sowie ein reduzierendes Polypeptid
ATE254663T1 (de) Erhöhte produktion von sekretierten proteinen durch rekombinante eukaryotische zellen
ATE216706T1 (de) Peptide des hiv-gag proteins, ihre herstellung und verwendung
DE69534738D1 (de) Leukocyten-aktivierender Faktor
AU637589B2 (en) Ancrod proteins, their production and use
TW342413B (en) Novel toxins isolated from Bracon Hebetor
CA2067334A1 (en) Recombinant production of lactoperoxidase
DE69420044D1 (de) Blutregulierende peptide
AU1275095A (en) Antiviral composition of viral protein trans-dominant variants
TH14767A (th) กระบวนการสำหรับแยกเอารีคอมบิแนนท์โปรตีนในรูปที่ออกฤทธิ์ทางชีววิทยาออกมาจากสารละลายที่มีโปรตีนที่ไม่ออกฤทธิ์อยู่ด้วย
RU93041779A (ru) Средство для лечения иммунодефицитных состояний

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee